ISCHEMAVIEW
15.5.2018 07:02:10 CEST | Business Wire | Press release
Today at the European Stroke Organization Conference, iSchemaView, the leader in automated cerebrovascular imaging analysis, publicly launched RAPID ASPECTS, a digital imaging solution that assists clinicians in assessing early signs of brain ischemia in stroke. RAPID ASPECTS automatically generates a standardized score — based on clinically validated machine learning algorithms — that enables physicians to easily communicate about the extent of a patient’s ischemic changes and to determine eligibility for thrombectomy (clot removal). In addition, RAPID ASPECTS provides clear visualization of the brain so that clinicians can better scrutinize each region and confirm the automated score. RAPID ASPECTS is CE-marked for use in Europe.
The original Alberta Stroke Program Early CT Score (ASPECTS) is a manual 10-point scoring system that relies on determining subtle changes in non-contrast CT examinations. This has traditionally required the expertise of an experienced neuroradiologist or stroke neurologist. Yet even stroke imaging experts have been shown to display significant scoring variability in most studies using ASPECTS . RAPID ASPECTS automates and standardizes the scoring process to help clinicians more accurately assess early signs of brain ischemia.
“In my opinion, using RAPID ASPECTS increases the likelihood of getting a reliable ASPECT score, independent of the individual skills and experience of the clinician. This tool is therefore particularly suitable for primary stroke centers with a smaller number of cases,” said Dr. Benjamin Friedrich, docent and physician in the Department of Diagnostic and Interventional Neuroradiology at the Klinikum rechts der Isar in Munich. “Early and reliable information makes it possible to quickly understand the prognosis of a patient.”
“ASPECT scoring plays a critical role in the treatment of brain ischemia leading to stroke and is part of the American Heart Association guidelines for use of endovascular therapy in patients who can be treated within six hours of symptom onset,” said Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of iSchemaView. “RAPID ASPECTS elevates the ASPECT scoring system, by providing clinicians with more reliable and reproducible scores and powerful visualization tools to support treatment decisions.”
RAPID ASPECTS receives data from standard CT scanners, tilt-corrects the images and identifies the ASPECTS regions. A sliding confidence indicator allows the physician to scrutinize suspicious regions and determine a final score. Moving the confidence slider to the left identifies additional regions that may potentially be involved, while moving the slider to the right removes regions with more subtle differences. In addition, RAPID ASPECTS includes these features:
- Slice up and down, zoom and window options that enable the clinician to evaluate different regions of interest
- Manual score adjustment by adding or subtracting regions
- Return to fully automated score with one click
“RAPID ASPECTS is the state-of-the-art offering for consistent, actionable ASPECT scoring,” said Don Listwin, CEO of iSchemaView. “Clinicians who use RAPID ASPECTS are better able to facilitate quick diagnoses and share information with internal care teams or specialty treatment centers for referrals. Whether it’s CTP, CTA, MRI or now ASPECTS, more than four hundred stroke centers worldwide are using RAPID imaging solutions to successfully identify and treat more stroke patients than ever before.”
Key Presentations at ESOC
iSchemaView cofounder, Dr. Greg Albers, will present at three sessions:
- “Key Subgroup Analyses From the DEFUSE 3 Study ” during the Presidential Symposium on Wednesday, May 16 at 15:00 in Hall C.
- “Validation of the Clinical/Core Mismatch and Perfusion/Core Mismatch Selection Criteria for Late Window Thrombectomy: Pooled Analysis of DEFUSE 3 And DAWN ” during the Reperfusion II session on Thursday, May 17 at 10:40 in Hall K3.
- Medtronic Care Continuum: Patient Pathway , Thursday, May 17, at 12:45 in Hall K1.
Dr. Benjamin Friedrich of the Department of diagnostic and interventional Neuroradiology at the Klinikum rechts der Isar will present a paper on automated ASPECTS scoring software, titled “Software-Based, Automated Calculation of the ASPECT Score In Patients Suffering From Emergent Vessel Occlusions in the Anterior Circulation – Clinical Feasibility And Reliability ,” during the Reperfusion Trials session on Friday, May 18 at 09:50 in Hall K2.
About iSchemaView
iSchemaView is the leader in cerebrovascular imaging analysis, delivering the proven software tools that healthcare professionals around the world use to successfully identify and treat more stroke patients than ever before. iSchemaView’s RAPID is the most advanced brain imaging platform, and in clinical trials, under IRB, RAPID has been shown to aid in the selection of patients in early and late window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN and DEFUSE 3. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, these landmark studies led to new American Heart Association and American Stroke Association guidelines and have dramatically altered the management of acute stroke around the world. For more information, visit www.iRAPID.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514006439/en/
Contact:
for iSchemaView
Peter Evers, 415-888-3314
Natron Communications
peter@natroncomm.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release
Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
